Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.77B |
$47.88
-1.26%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Company focuses on oncology therapeutics, including Revuforj and Niktimvo, placing Syndax in Biotech - Oncology.
|
$1.77B |
$20.50
-0.82%
|
|
ZYME
Zymeworks Inc.
Zymeworks develops oncology therapeutics, including zanidatamab and multiple ADC/MSAT platform programs.
|
$1.76B |
$23.48
-0.61%
|
|
SION
Sionna Therapeutics, Inc.
Lead candidates are oral small-molecule therapeutics (SION-719, SION-451) in clinical development.
|
$1.73B |
$39.12
+0.71%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.70B |
$25.66
-0.12%
|
|
PRCT
PROCEPT BioRobotics Corporation
PROCEPT's Aquablation robotic systems are surgical equipment sold for urology procedures.
|
$1.69B |
$30.38
-0.39%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.68B |
$33.29
+1.65%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.67B |
$31.00
+0.32%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$1.66B |
$40.99
+2.32%
|
|
NEO
NeoGenomics, Inc.
They provide comprehensive laboratory testing services and advisory support for oncology diagnostics.
|
$1.65B |
$12.78
-0.43%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.63B |
$6.75
-4.12%
|
|
ELVN
Enliven Therapeutics, Inc.
Directly develops oncology therapeutics (small-molecule kinase inhibitors) for cancer, including lead assets ELVN-001 (BCR-ABL) and ELVN-002 (HER2).
|
$1.58B |
$26.71
+6.14%
|
|
ENOV
Enovis Corporation
Directly produces orthopedic devices and implants used in reconstructive surgery.
|
$1.58B |
$27.93
+0.94%
|
|
AGIO
Agios Pharmaceuticals, Inc.
Agios's strategic pivot to rare diseases centers on PK activation therapies and a pipeline addressing rare hematologic conditions, aligning with Biotech - Rare Diseases.
|
$1.58B |
$27.20
-2.18%
|
|
STOK
Stoke Therapeutics, Inc.
TANGO uses antisense oligonucleotides to upregulate the healthy gene copy, directly categorizing the company’s core assets as an oligonucleotide therapeutic.
|
$1.57B |
$28.70
-1.96%
|
|
TYRA
Tyra Biosciences, Inc.
TYRA-300 is an oral FGFR3-selective small-molecule inhibitor; TYRA develops oral small-molecule therapeutics.
|
$1.53B |
$28.77
-0.86%
|
|
NVCR
NovoCure Limited
NovoCure's TTFields cancer therapy device (Optune) is a medical device sold to treat cancer, fitting the Medical Devices & Biometrics category.
|
$1.52B |
$13.62
-1.34%
|
|
FTRE
Fortrea Holdings Inc.
Fortrea operates as a standalone contract research organization providing outsourced clinical development services.
|
$1.49B |
$16.52
+3.48%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.47B |
$19.21
+1.88%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.46B |
$23.70
-1.58%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$1.45B |
$13.00
+11.21%
|
|
TWFG
TWFG, Inc. Common Stock
Distributes health insurance products.
|
$1.44B |
$25.63
-2.81%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.44B |
$45.56
-2.86%
|
|
AHCO
AdaptHealth Corp.
Direct provider of Home Health & Hospice services and in-home patient care.
|
$1.44B |
$10.60
-0.38%
|
|
KOD
Kodiak Sciences Inc.
Kodiak is developing ophthalmic drugs (intravitreal biologics) for retinal diseases, making Ophthalmic Drugs a core product category.
|
$1.43B |
$27.15
+1.69%
|
|
AXGN
AxoGen, Inc.
Axogen's Avance Nerve Graft and Axoguard nerve-repair products are surgical devices used in peripheral nerve repair.
|
$1.43B |
$31.07
-0.48%
|
|
CTS
CTS Corporation
CTS targets medical end-markets with diagnostic/sensor applications; tagged under Medical Devices & Biometrics.
|
$1.42B |
$48.39
-0.02%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.42B |
$44.26
+0.58%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$1.41B |
$25.23
+5.83%
|
|
TIC
TIC Solutions, Inc.
Laboratory Testing & Advisory Services aligns with Acuren's lab-based destructive testing capabilities and analytical advisory work.
|
$1.40B |
$11.45
-1.68%
|
|
BCRX
BioCryst Pharmaceuticals, Inc.
ORLADEYO is BioCryst's flagship oral small-molecule therapy for hereditary angioedema, a core product.
|
$1.40B |
$6.66
-7.18%
|
|
BHVN
Biohaven Ltd.
BHV-1510 is a next-generation Antibody Drug Conjugate (ADC) targeting Trop2, a key oncology modality.
|
$1.39B |
$13.13
+10.15%
|
Showing page 12 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
